Latest News and Press Releases

BOTHELL, Wash., July 13, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing its solely-owned pivotal-stage product candidate...

BOTHELL, Wash., July 12, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing its solely-owned pivotal-stage product candidate...

BOTHELL, Wash., July 11, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing its solely-owned pivotal-stage product candidate...

-- Pivotal PROMISE 1 top-line results show eptinezumab met primary and key secondary endpoints -- -- Beginning day 1 after first dose significant reduction in proportion of patients experiencing...

BOTHELL, Wash., June 07, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), today announced four data presentations at the 59th Annual Scientific Meeting of the American Headache...

BOTHELL, Wash., May 10, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today announced...

- Eptinezumab emerging clinical profile suggests migraine preventative benefit achieved as soon as 24 to 48 hours after a single infusion - BOTHELL, Wash., April 28, 2017 (GLOBE NEWSWIRE) --...

Top-line data from pivotal PROMISE 1 study of eptinezumab for migraine prevention on track to be announced 2Q 2017Conference call set for 5 p.m. EDT todayBOTHELL, Wash., April 27, 2017 (GLOBE...

- Eptinezumab rational design results in differentiated clinical profile for migraine prevention therapy - - Eptinezumab responders showed significant and sustained reduction in migraine days...

BOTHELL, Wash., April 20, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals®, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics, today...